

What is claimed:

1. A method for the prevention or treatment of an extravascular hematoma or blood clot in a subject, comprising administering to the subject a therapeutically effective
5 amount of a thrombolytic agent, thereby preventing or treating the extravascular hematoma or blood clot.

2. The method of claim 1, wherein the blood clot is associated with intraventricular hemorrhage.
10

3. The method of claim 2, wherein the blood clot is further associated with intracerebral hemorrhage.

4. The method of claim 1, wherein the blood clot is associated with subarachnoid hemorrhage.
15

5. The method of any of claims 1-4, wherein the thrombolytic agent is urokinase.

6. The method of any of claims 1-4, wherein the thrombolytic agent is t-PA or rt-PA.
20

7. The method of any of claims 1-6, wherein the thrombolytic agent is administered in conjunction with EVD.

25 8. The method of any of claims 1-7, wherein the thrombolytic agent is first administered between about 12-24 hours after diagnosis of intraventricular hemorrhage, intracerebral hemorrhage, and/or subarachnoid hemorrhage.

9. The method of any of claims 1-7, wherein the thrombolytic agent is first
30 administered between about 24-48 hours after diagnosis of intraventricular hemorrhage, intracerebral hemorrhage, and/or subarachnoid hemorrhage.

10. The method of any of claims 1-9, further comprising performing CT scans at intervals of about 6-24 hours to monitor blood clot size and/or monitor whether bleeding is occurring.

5 11. The method of any of claims 1-10, wherein the thrombolytic agent is administered at least about every 4 hours.

12. The method of any of claims 1-11, wherein the thrombolytic agent is administered at least about every 6 hours.

10

13. The method of any of claims 1-12, wherein the thrombolytic agent is administered at least about every 8 hours.

14. The method of any of claims 1-13, wherein the thrombolytic agent is
15 administered at least about every 10 hours.

15. The method of any of claims 1-14, wherein the thrombolytic agent is administered at least about every 12 hours.

20 16. The method of any of claims 1-15, wherein administration of the thrombolytic agent is stopped when the blood clot size is about 80% of its original size.

17. The method of claim 16, wherein the blood clot reaches 80% of its original size about 3 days after the first administration of the thrombolytic agent.

25

18. The method of any of claims 5 or 7-17, wherein the urokinase is administered in doses of about 5000-50,000 units.

19. The method of claim 18, wherein the urokinase is administered in doses of
30 about 12,500 units.

20. The method of any of claims 6-17, wherein the t-PA or rt-PA is administered in doses of about 0.1-10 mg.

21. The method of claim 20, wherein the t-PA or rt-PA is administered in doses of about 3 mg.